Quick Answer: Why Does Tirzepatide Target Both GLP-1 and GIP?
Tirzepatide is fundamentally different from a conventional selective GLP-1 receptor agonist because one molecule activates two incretin receptors: the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR).
This dual agonism changed the weight-management conversation because it demonstrated that simultaneously targeting two nutrient-responsive hormonal pathways could produce substantial metabolic and body-weight effects.
In the 72-week SURMOUNT-1 trial, adults with obesity or overweight without diabetes receiving tirzepatide experienced mean weight reductions of 15.0%, 19.5%, and 20.9% with 5 mg, 10 mg, and 15 mg respectively, compared with 3.1% with placebo.
However, the science is more nuanced than saying “GIP makes GLP-1 stronger.” The exact contribution of GIP receptor activation to tirzepatide’s human effects remains an active research question.
The key scientific idea is therefore not simply more weight loss.
It is the shift from single-receptor incretin pharmacology toward multi-receptor metabolic signaling.
Key Takeaways
- Tirzepatide is a single synthetic peptide designed to activate both GIP and GLP-1 receptors.
- GLP-1 receptor activation is associated with glucose-dependent insulin secretion, reduced glucagon signaling, appetite regulation and delayed gastric emptying.
- GIP is another nutrient-responsive incretin hormone with important effects on pancreatic insulin secretion and broader metabolic regulation.
- Combining GIPR and GLP-1R agonism in one molecule created a new pharmacological strategy rather than simply increasing GLP-1 activity.
- SURMOUNT-1 demonstrated substantial and sustained weight reduction over 72 weeks in adults with obesity or overweight without diabetes.
- SURPASS-2 showed that tirzepatide produced greater glycemic control and weight reduction than once-weekly semaglutide 1 mg in adults with type 2 diabetes.
- SURMOUNT-5 subsequently found tirzepatide superior to semaglutide for weight reduction and waist circumference in adults with obesity without diabetes.
- The exact biological contribution of GIP receptor activation to tirzepatide’s clinical effects remains incompletely resolved.
- Dual agonism should not be interpreted as simply “two GLP-1 effects.” GIP and GLP-1 have overlapping but distinct physiological roles.
- Tirzepatide is clinically established for specific approved indications in some regulatory jurisdictions; research-peptide products should not be conflated with approved pharmaceutical products.
Introduction: The Important Change Was Not Just the Amount of Weight Lost
The modern weight-management field has been strongly influenced by incretin biology.
GLP-1 receptor agonists demonstrated that pharmacologically modifying an endogenous gut-hormone pathway could substantially alter appetite, glucose regulation and body weight.
Tirzepatide introduced a different concept.
Instead of selectively activating one incretin receptor, researchers developed a single molecule capable of activating two:
- GLP-1 receptor
- GIP receptor
This is known as dual agonism or co-agonism.
The significance is pharmacological.
The molecule is not simply a stronger version of a traditional GLP-1 receptor agonist. It represents an attempt to coordinate two nutrient-sensitive signaling systems within one therapeutic molecule.
That distinction is important when discussing tirzepatide scientifically.
What Is GLP-1?
Glucagon-like peptide-1, or GLP-1, is an incretin hormone produced by enteroendocrine cells, particularly after nutrient ingestion.
GLP-1 receptor signaling has several well-characterized physiological effects.
- It enhances glucose-dependent insulin secretion.
- It suppresses glucagon secretion when glucose concentrations are elevated.
- It slows gastric emptying.
- It contributes to central regulation of appetite and food intake.
These effects help explain why GLP-1 receptor agonism became an important therapeutic strategy for type 2 diabetes and obesity.
But GLP-1 is only one part of the incretin system.
What Is GIP?
Glucose-dependent insulinotropic polypeptide, commonly abbreviated as GIP, is another incretin hormone released in response to nutrient ingestion.
Historically, GIP received less attention in obesity pharmacology than GLP-1.
Its biological role is more complicated than simply “another GLP-1.”
GIP receptor signaling contributes to glucose-dependent insulin secretion and interacts with metabolic pathways involving pancreatic tissue, adipose tissue and the central nervous system.
Importantly, the physiological response to GIP can depend on metabolic context.
This is one reason why the development of a pharmacological GIP/GLP-1 co-agonist represented a significant conceptual shift.
Tirzepatide: One Molecule, Two Receptors
Tirzepatide is a synthetic peptide engineered from the GIP sequence and modified to produce prolonged exposure.
It contains a fatty diacid side chain that promotes albumin binding, contributing to a pharmacokinetic profile compatible with once-weekly administration.
Pharmacologically, it acts as an agonist at both GIPR and GLP-1R.
GIP receptor agonism + GLP-1 receptor agonism
↓
Integrated incretin signaling
This architecture is the defining scientific feature of tirzepatide.
Why Combine GIP and GLP-1?
The rationale for dual agonism comes from the observation that GIP and GLP-1 participate in overlapping metabolic processes but are not biologically identical.
A simplified comparison looks like this:
| Feature | GLP-1 | GIP |
|---|---|---|
| Hormone class | Incretin | Incretin |
| Primary receptor | GLP-1 receptor | GIP receptor |
| Insulin secretion | Glucose-dependent stimulation | Glucose-dependent stimulation |
| Glucagon regulation | Important suppressive effect under hyperglycemic conditions | Context-dependent effects |
| Appetite / energy intake | Strongly implicated | Increasingly recognized as relevant |
| Gastric emptying | Slows gastric emptying | Different / less dominant role |
The therapeutic hypothesis is that appropriately combining these pathways may generate a metabolic response that differs from selective GLP-1 receptor activation.
Dual Agonism Is Not Simply “More GLP-1”
This is one of the most important misconceptions to avoid.
Tirzepatide does not work because it is merely a higher-potency version of a conventional GLP-1 receptor agonist.
It is pharmacologically distinct.
Its molecular design intentionally incorporates GIP receptor activity as well as GLP-1 receptor activity.
However, the exact interaction between the two pathways is still debated.
A 2023 pharmacology review concluded that the contribution of GIP receptor activation to tirzepatide’s human effects is not completely resolved. Experimental data suggest that tirzepatide has a distinctive GLP-1 receptor signaling profile and that GIP receptor signaling may contribute through mechanisms more complicated than a simple additive model.
Therefore, a scientifically responsible description is:
The precise biological reason it produces such strong clinical effects is still being investigated.
The First Major Clinical Proof: SURPASS-2
Before tirzepatide became central to the obesity conversation, its clinical development was strongly connected to type 2 diabetes.
The SURPASS-2 trial compared once-weekly tirzepatide at 5 mg, 10 mg and 15 mg with once-weekly semaglutide 1 mg in adults with type 2 diabetes receiving metformin.
The importance of the study was not simply that tirzepatide lowered glucose.
It provided a direct clinical comparison between a dual GIP/GLP-1 agonist and a selective GLP-1 receptor agonist.
Tirzepatide produced greater reductions in HbA1c and body weight than semaglutide 1 mg in the trial population.
This comparison helped establish the idea that dual incretin receptor targeting could produce a distinct clinical profile.
SURMOUNT-1: The Weight-Management Conversation Changes
The obesity-specific evidence became especially influential with SURMOUNT-1.
This phase 3 trial enrolled 2,539 adults with obesity or overweight plus at least one weight-related complication, excluding people with diabetes.
Participants were randomized to once-weekly tirzepatide 5 mg, 10 mg, 15 mg or placebo for 72 weeks.
The results were striking.
| Group | Mean Weight Change at Week 72 | Participants Achieving ≥5% Weight Loss |
|---|---|---|
| Tirzepatide 5 mg | -15.0% | 85% |
| Tirzepatide 10 mg | -19.5% | 89% |
| Tirzepatide 15 mg | -20.9% | 91% |
| Placebo | -3.1% | 35% |
Importantly, the trial also demonstrated improvements across prespecified cardiometabolic measures.
These findings helped shift the conversation around obesity pharmacology from the question of whether medication can produce modest weight reduction toward the possibility of achieving much larger, sustained reductions in body weight.
Why the GIP Component Became So Interesting
If selective GLP-1 receptor agonism can already produce substantial weight loss, why add GIP receptor activity?
That question remains central to tirzepatide research.
Several hypotheses have been proposed.
- GIP receptor signaling may complement GLP-1 receptor signaling in metabolic tissues.
- GIP may influence insulin secretion and glucose handling in a glucose-dependent manner.
- GIP signaling may interact with central pathways regulating energy intake.
- GIP activity may modify some of the tolerability characteristics of GLP-1-based pharmacology.
- Combined signaling may produce a metabolic state that differs from selective GLP-1 receptor activation.
However, these hypotheses should not be treated as equally proven.
The strongest evidence is currently clinical: tirzepatide works very well in the studied populations.
The precise molecular explanation for why dual agonism produces this magnitude of effect remains an active scientific question.
The Central Nervous System Adds Another Layer
Weight regulation is not controlled by a single organ.
Both GLP-1 and GIP receptors are expressed in tissues involved in metabolic regulation, including the central nervous system.
GLP-1 receptor signaling in the brain can influence satiety and food intake.
The contribution of GIP receptor signaling is more complex.
Preclinical studies have produced apparently conflicting observations in which both activation and inhibition of central GIP receptors can influence body weight.
This means that simply drawing a diagram showing “GIP receptor activation → appetite suppression” would oversimplify the biology.
The modern interpretation is more cautious:
Dual Agonism and Glucose Regulation
Weight reduction is only one part of tirzepatide’s clinical pharmacology.
Both GLP-1 and GIP are incretin hormones, meaning they contribute to insulin secretion in response to nutrient ingestion.
Because the insulinotropic effects are glucose-dependent, incretin-based therapies can improve glycemic control without behaving like direct insulin replacement.
Tirzepatide therefore operates across several interconnected physiological domains:
- postprandial insulin signaling;
- glucose regulation;
- appetite and energy intake;
- gastric emptying;
- body-weight regulation;
- and broader cardiometabolic variables.
This is another reason why calling tirzepatide simply a “fat-loss peptide” misses its pharmacological identity.
Tirzepatide Is Not a Direct Fat-Burning Molecule
The phrase “fat burner” is scientifically misleading when applied to tirzepatide.
The dominant clinical effect is not a direct pharmacological combustion of adipose tissue.
Weight reduction occurs within a broader metabolic response involving reduced energy intake, altered appetite signaling, glucose regulation and changes in body composition.
Clinical studies have demonstrated reductions in body weight and fat mass, but that does not mean tirzepatide directly “burns fat” in the way the phrase is often used in supplement marketing.
A more accurate description is:
Tirzepatide modifies nutrient-sensing and metabolic signaling through combined GIP and GLP-1 receptor agonism, producing substantial changes in energy intake, glycemic control and body weight.
The Head-to-Head Test: Tirzepatide vs Semaglutide
The dual-agonism hypothesis became even more interesting when tirzepatide was tested directly against a selective GLP-1 receptor agonist in obesity.
The 2025 SURMOUNT-5 trial randomized adults with obesity but without type 2 diabetes to maximum tolerated doses of tirzepatide or semaglutide for 72 weeks.
Tirzepatide was superior to semaglutide for reduction in body weight and waist circumference.
This is important because the comparison was not:
drug versus placebo.
It was:
dual GIP/GLP-1 agonism versus selective GLP-1 receptor agonism.
That makes SURMOUNT-5 particularly relevant to the scientific question behind this article.
But a Head-to-Head Advantage Does Not Prove the Mechanism
This distinction is subtle but important.
If tirzepatide produces greater weight loss than semaglutide, that establishes a clinical difference between the treatments.
It does not prove that the entire difference is caused by GIP receptor activation alone.
Other pharmacological differences exist between the molecules, including receptor signaling profiles, molecular structure, exposure and pharmacokinetics.
Therefore, researchers continue to investigate precisely how GIP receptor activity contributes to tirzepatide’s effects.
Dual Agonism vs Selective GLP-1 Agonism
| Feature | Selective GLP-1RA | Tirzepatide |
|---|---|---|
| Primary receptor strategy | GLP-1 receptor | GLP-1 + GIP receptors |
| Molecular design | Selective receptor agonism | Single-molecule dual agonism |
| Glucose-dependent insulinotropic signaling | Yes | Yes through both incretin pathways |
| Appetite regulation | Established component | Established, with additional GIP signaling |
| Weight-loss evidence | Substantial | Very substantial; superior to semaglutide in SURMOUNT-5 |
| Mechanistic certainty | Relatively well characterized | Dual-receptor pharmacology established; exact GIP contribution remains under investigation |
What Does “Dual” Actually Mean?
“Dual” refers to the number of receptor targets activated by the same therapeutic molecule.
It does not mean:
- two separate injections;
- two separate peptides mixed together;
- twice the dose;
- or simply double the effect.
Tirzepatide is a single molecular entity with activity at two incretin receptors.
This distinction becomes particularly important when comparing tirzepatide with research stacks containing separate peptides.
A two-peptide combination is pharmacologically different from a single dual-receptor agonist.
Why One Molecule Matters
Combining receptor activity within one molecule offers several theoretical pharmacological advantages.
Both receptor activities are delivered through the same molecular exposure profile.
The pharmacokinetic relationship between the two activities is therefore inherently linked.
This differs from administering two independent drugs, where absorption, distribution, metabolism and clearance may occur differently.
That does not automatically mean a single dual agonist is superior to every combination therapy.
It means the molecule was designed to coordinate two receptor activities within one pharmacological framework.
Why the Weight-Management Conversation Changed
The significance of tirzepatide is therefore broader than its percentage of weight reduction.
It demonstrated that metabolic pharmacology could be designed around multiple coordinated hormone receptors.
This idea has influenced the next generation of incretin research.
Researchers are now investigating:
- dual agonists;
- triple agonists;
- different receptor-bias profiles;
- longer-acting incretin molecules;
- and combinations targeting additional metabolic pathways.
Tirzepatide sits at an important point in this progression.
It showed that moving beyond selective GLP-1 receptor agonism could produce a clinically meaningful difference.
Safety Still Belongs in the Dual-Agonism Discussion
A sophisticated discussion of tirzepatide cannot focus exclusively on efficacy.
Because GLP-1 and GIP signaling affects the gastrointestinal and metabolic systems, adverse effects can occur.
In SURMOUNT-1, the most common adverse events were gastrointestinal and were generally mild to moderate, occurring particularly during dose escalation.
Treatment discontinuation due to adverse events occurred in 4.3%, 7.1%, 6.2% and 2.6% of participants receiving 5 mg, 10 mg, 15 mg and placebo, respectively.
This illustrates an important principle:
Greater pharmacological activity does not mean greater biological simplicity.
The same multi-pathway pharmacology that produces substantial metabolic effects also requires careful clinical evaluation of tolerability and safety.
Tirzepatide Is Now More Than a Weight-Management Molecule
The clinical development program has expanded beyond the original diabetes-focused question.
Tirzepatide has demonstrated effects across glycemic control, body weight and several cardiometabolic parameters.
In 2024, the FDA also approved Zepbound, the tirzepatide brand for obesity-related indications, for treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, alongside reduced-calorie diet and increased physical activity.
This regulatory development illustrates how the clinical relevance of incretin pharmacology is expanding into conditions closely linked with metabolic disease.
However, each indication still requires evidence specific to the disease and population being treated.
The Ho Chi Minh City Lens: Why Dual Agonism Matters to an International Wellness Audience
Ho Chi Minh City has a rapidly evolving health, fitness and wellness environment where international residents may encounter information about GLP-1 therapies, research peptides and next-generation metabolic drugs from multiple countries.
That environment makes pharmacological literacy important.
The phrase “GLP-1 peptide” is now used very broadly online.
But not every incretin molecule has the same receptor profile.
The scientifically important distinction is:
versus
Dual GIP + GLP-1 receptor agonism
Tirzepatide belongs to the second category.
Understanding that difference helps international readers evaluate claims without reducing every incretin therapy to the generic phrase “weight-loss injection.”
What Tirzepatide Does Not Mean
- It does not mean that GIP and GLP-1 effects are simply doubled.
- It does not mean that every person will experience the same degree of weight reduction.
- It does not mean that tirzepatide directly burns adipose tissue like a stimulant.
- It does not mean that every research formulation is equivalent to an approved pharmaceutical product.
- It does not mean that the precise mechanism of GIP contribution is completely settled.
- It does not eliminate the importance of nutrition, physical activity, sleep or other determinants of metabolic health.
Statistics & Evidence Snapshot
| Evidence Point | Finding | Why It Matters |
|---|---|---|
| SURPASS-2 | Tirzepatide outperformed semaglutide 1 mg for HbA1c and weight reduction in T2D | Direct comparison with selective GLP-1R agonism |
| SURMOUNT-1 | 2,539 adults; 72 weeks | Large obesity efficacy trial |
| SURMOUNT-1, 15 mg | Mean weight change -20.9% | Demonstrated magnitude of effect |
| SURMOUNT-1, 10 mg | Mean weight change -19.5% | Substantial sustained weight reduction |
| SURMOUNT-5 | Tirzepatide superior to semaglutide at 72 weeks | Strengthens the clinical relevance of dual agonism |
| Mechanistic question | Exact contribution of GIPR signaling remains incompletely resolved | Prevents oversimplification of the mechanism |
Expert Insight #1: The Important Innovation Is Receptor Architecture
Expert Insight: Tirzepatide should be understood as a pharmacological architecture rather than simply a high-performance weight-loss peptide. Its defining feature is the intentional combination of GIP and GLP-1 receptor agonism within one molecule. The clinical results are impressive, but the mechanistic question remains open: exactly how GIP receptor signaling contributes to the overall phenotype is still being investigated.
Expert Insight #2: Clinical Superiority Does Not Equal Mechanistic Certainty
Expert Insight: SURMOUNT-5 provides important clinical evidence that tirzepatide can produce greater weight reduction than semaglutide in the studied population. But a superior clinical result does not isolate the contribution of GIP receptor activation from all other molecular differences between the drugs. Clinical efficacy and mechanistic attribution are related but separate scientific questions.
Frequently Asked Questions
Tirzepatide is a dual GIP and GLP-1 receptor agonist. A conventional selective GLP-1 receptor agonist primarily targets GLP-1R.
It means one therapeutic molecule activates two receptor systems. In tirzepatide, these are the GIP receptor and GLP-1 receptor.
No. Both are incretin hormones, but they have distinct receptor systems and overlapping as well as different physiological effects.
The research hypothesis is that coordinated activation of both incretin pathways can produce a different and potentially stronger metabolic response than selective GLP-1 receptor agonism alone.
No. Dual agonism is not equivalent to doubling GLP-1 receptor stimulation. Tirzepatide has a distinct pharmacological profile involving both GIPR and GLP-1R.
In 2,539 adults with obesity or overweight without diabetes, 72 weeks of tirzepatide produced mean weight reductions of 15.0%, 19.5% and 20.9% with 5 mg, 10 mg and 15 mg, respectively, compared with 3.1% with placebo.
Yes. SURPASS-2 showed greater glycemic and weight reductions versus semaglutide 1 mg in type 2 diabetes, while SURMOUNT-5 later found tirzepatide superior to semaglutide for body weight and waist circumference in adults with obesity without diabetes.
Not by itself. The head-to-head clinical results support a difference between tirzepatide and selective GLP-1 receptor agonism, but they do not isolate GIP receptor signaling as the sole explanation.
That is an oversimplification. Tirzepatide changes nutrient-sensitive hormonal signaling, appetite, energy intake and glucose metabolism, resulting in substantial changes in body weight and body composition.
The term refers to its ability to activate both GIP and GLP-1 receptor pathways, effectively combining two incretin pharmacologies in one molecule.
No. Tirzepatide is a single synthetic peptide engineered to activate both receptor systems.
No. GIP receptor activation is clearly part of tirzepatide’s pharmacology, but the precise contribution of GIP signaling to the human clinical effects remains an active area of research.
Tirzepatide is an approved pharmaceutical in several jurisdictions for specific indications, including type 2 diabetes and obesity-related indications in the United States. Approval status and indications vary by country. Research-grade tirzepatide products should not be represented as equivalent to an approved pharmaceutical product.
No. A pen is a delivery format. Regulatory status depends on the identity, manufacturing quality, formulation, authorization and intended use of the specific product.
Tirzepatide demonstrated that coordinated targeting of multiple metabolic receptors can produce clinically meaningful effects. This has encouraged research into next-generation dual and triple receptor agonists.
Related Articles
- Vietnam Peptides Knowledge Hub: Peptide Research & Education
- Peptide FAQ: Research, Storage and Usage Questions
- Peptide Products for Recovery, Longevity & Performance Research
- Personalized Peptide Plans for Recovery, Fat Loss & Longevity Research
Related Research Products
Premium Tirzepatide 20mg Injection Pen
A research-oriented injection-pen format centered on tirzepatide and its dual GIP/GLP-1 receptor pharmacology. Product format should not be confused with regulatory approval or clinical evidence for a specific research formulation.
Premium Tesamorelin 10mg Injection Pen
A research peptide product targeting a fundamentally different biological pathway. Comparing receptor mechanisms can help illustrate why different peptide classes should not be grouped together simply as “fat-loss peptides.”
Fat Loss Peptide Plan
Readers researching the broader pharmacology of peptides associated with metabolic and body-composition research can explore the Fat Loss Peptide Plan. This resource is provided for educational and research-planning purposes and is not individualized medical treatment guidance.
Scientific References
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385:503-515. PMID: 34170647. DOI: 10.1056/NEJMoa2107519.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216. PMID: 35658024. DOI: 10.1056/NEJMoa2206038.
- Gasbjerg LS, Rosenkilde MM, Meier JJ, Holst JJ, Knop FK. The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide. Diabetes Obes Metab. 2023;25(11):3054-3064. PMID: 37551549. DOI: 10.1111/dom.15216.
- Samson SL, Garber AJ. GLP-1 receptor agonists and GIP/GLP-1 receptor co-agonists in metabolic disease. Review of incretin pharmacology and metabolic effects.
- Nowak M, Nowak W, Grzeszczak W. Tirzepatide – a dual GIP/GLP-1 receptor agonist – a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes. Endokrynol Pol. 2022;73(4):745-755. PMID: 35593668. DOI: 10.5603/EP.a2022.0029.
- Aronne LJ, Bade Horn D, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393:26-36. PMID: 39494251. DOI: 10.1056/NEJMoa2416394.
- Knop FK, Aaboe K, Vilsbøll T, et al. GIP and GLP-1 receptor agonism and the metabolic effects of tirzepatide. Related incretin pharmacology literature.
- Finan B, Douros JD, Capozzi ME, et al. Unimolecular dual and triple agonists for metabolic disease. Related preclinical literature on multi-receptor agonism.
- Urva S, Coskun T, Loh MT, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes. Diabetes Care. 2018;41(12):2646-2654. PMID: 30287476.
- Willard FS, Douros JD, Gabe MBN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. PMID: 32856314. DOI: 10.1172/jci.insight.140532.
- Ghaleb J, et al. Unveiling Tirzepatide’s Therapeutic Spectrum: A Dual GIP/GLP-1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health. Int J Endocrinol. 2025;2025:2876156. PMID: 41069980. DOI: 10.1155/ije/2876156.
- Liu S, Yu X, Jin X, Sheng L. The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review. 2025. PMID: 41312047.
Conclusion
Tirzepatide changed the weight-management conversation for a reason that goes beyond its impressive percentage of weight reduction.
Its defining innovation is dual receptor pharmacology.
Rather than selectively activating GLP-1R, tirzepatide activates both GLP-1R and GIPR within a single molecular framework.
That design created a new question in metabolic medicine:
Clinical evidence strongly supports the importance of this strategy.
SURPASS-2 showed greater glycemic and weight effects than semaglutide 1 mg in type 2 diabetes. SURMOUNT-1 demonstrated substantial sustained weight reduction in adults with obesity or overweight without diabetes. SURMOUNT-5 subsequently showed that tirzepatide was superior to semaglutide for weight and waist reduction in adults with obesity.
But the mechanistic story should remain nuanced.
The presence of GIP receptor agonism is established. The exact contribution of GIP signaling to the overall human effect of tirzepatide is still being investigated.
That distinction matters because the next generation of metabolic peptides will increasingly be defined not simply by how much they affect body weight, but by which receptor combinations they target and how those signals interact.
It demonstrated the clinical potential of coordinated GIP + GLP-1 receptor pharmacology.
For readers in Ho Chi Minh City navigating the increasingly crowded peptide and metabolic-health landscape, understanding that distinction is far more useful than simply labeling tirzepatide a “weight-loss injection.”
Quick Answer
Core Questions: What makes tirzepatide different from GLP-1? What is dual GLP-1/GIP agonism? How does GIP contribute to tirzepatide? Why is tirzepatide more effective than some GLP-1 drugs? What did SURMOUNT-1 show? What did SURMOUNT-5 show? Is tirzepatide a fat burner? What is the difference between GIP and GLP-1?
Evidence Level: Extensive phase 3 clinical evidence for tirzepatide in approved indications; strong evidence for substantial weight and glycemic effects; ongoing mechanistic research into the precise contribution of GIP receptor activation.